In settlement, Mylan doesn’t admit guilt for misclassifying life-saving device.
Source: For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million | Ars Technica
In settlement, Mylan doesn’t admit guilt for misclassifying life-saving device.
Source: For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million | Ars Technica
The CEO of a former Fortune 500 company, who is also the daughter of a U.S. senator, is under fire for jacking up the rates of a life-saving anti-allergy treatment.
Source: EpiPen Uproar Highlights Company’s Family Ties to Congress